¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"chain termination mutation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • chain saw
    »ç½½Åé
  • chromosome chain
    ¿°»öü»ç½½, ¿°»öü°í¸®
  • food chain
    ¸ÔÀ̻罽
  • gamma chain disease
    °¨¸¶»ç½½º´
  • heavy chain
    ¹«°Å¿î»ç½½, Áß¼â
  • heavy-chain disease
    ¹«°Å¿î»ç½½º´, Á߼⺴
  • hemolytic chain
    ¿ëÇ÷»ç½½
  • joining chain
    ¿¬°á»ç½½
  • lateral chain
    °ç»ç½½
  • light chain
    °¡º­¿î»ç½½, °æ¼â
  • light chain disease
    °¡º­¿î»ç½½º´, °æ¼âº´
  • light-chain nephropathy
    °¡º­¿î»ç½½ÄáÆÏº´(Áõ), °æ¼â½ÅÀ庴(Áõ)
  • nuclear chain
    Çٻ罽
  • nuclear chain fiber
    Çٻ罽¼¶À¯, Çٻ罽±Ù(À°)¼¼Æ÷
  • open chain
    ¿­¸°»ç½½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • mutation detection
    µ¹¿¬º¯À̰ËÃâ
  • extragenic suppressor mutation
    À¯ÀüÀڿܹßÇö¾ïÁ¦µ¹¿¬º¯ÀÌ
  • forward mutation
    ÀüÇâµ¹¿¬º¯ÀÌ
  • frequency mutation
    µ¹¿¬º¯À̺óµµ
  • genetic mutation
    À¯Àüµ¹¿¬º¯ÀÌ
  • genomic mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ, À¯Àüüµ¹¿¬º¯ÀÌ
  • mutation genetics
    º¯ÀÌÀ¯ÀüÇÐ
  • host range mutation
    ¼÷ÁÖ¹üÀ§º¯ÀÌ, ¼÷ÁÖ¿ªº¯ÀÌ
  • induced mutation
    À¯¹ßµ¹¿¬º¯ÀÌ
  • loss mutation
    »ó½Çµ¹¿¬º¯ÀÌ
  • mutation
    µ¹¿¬º¯ÀÌ
  • missense mutation
    °ú¿Àµ¹¿¬º¯ÀÌ
  • multiple allelic mutation
    ¹µ¸Â¼¶µ¹¿¬º¯ÀÌ
  • mutation rate
    µ¹¿¬º¯ÀÌÀ²
  • natural mutation
    ÀÚ¿¬µ¹¿¬º¯ÀÌ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • mutation, nonsense
    ¹«ÀÇ¹Ì µ¹¿¬º¯ÀÌ, ³­¼¾½º µ¹¿¬º¯ÀÌ
  • mutation, plaque-type
    ÇöóÅ©Çü µ¹¿¬º¯ÀÌ
  • mutation, point
    Á¡ µ¹¿¬º¯ÀÌ
  • mutation, polar
    ±Ø¼ºÈ¿°ú°¡ ³ª´Âµ¹¿¬º¯ÀÌ
  • mutation, reading frame
    ÇØµ¶Æ² µ¹¿¬º¯ÀÌ
  • mutation, recessive
    ¿­¼º µ¹¿¬º¯ÀÌ
  • mutation, reversible
    °¡¿ª¼º µ¹¿¬º¯ÀÌ
  • mutation, somatic
    ü¼¼Æ÷µ¹¿¬º¯ÀÌ
  • mutation, spontaneous
    ÀÚ¿¬µ¹¿¬º¯ÀÌ
  • mutation, suppressor
    ¾ïÁ¦ µ¹¿¬º¯ÀÌ (¹ßÇö)
  • natural mutation
    ÀÚ¿¬(µ¹¿¬)º¯ÀÌ(~ÔÍæÔܨì¶).
  • nonsense mutation
    ³­¼¾½º(µ¹¿¬)º¯ÀÌ(~ÔÍæÔܨì¶).
  • plaque morphology mutation
    ÇöóÅ© ÇüÅ µ¹¿¬º¯ÀÌ
  • plaque-type mutation
    ÇöóÅ©Çü µ¹¿¬º¯ÀÌ
  • point mutation
    Á¡ µ¹¿¬º¯ÀÌ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • silent mutation
    ħ¹¬ º¯ÀÌ(öØÙùܨì¶)
  • single-site mutation
    ¿ÜÀÚ¸® º¯ÀÌ(ܨì¶)
  • somatic mutation
    ü¼¼Æ÷ º¯ÀÌ(ô÷á¬øàܨì¶)
  • somatic mutation theory
    ü¼¼Æ÷ º¯ÀÌÀÌ·Ð(ô÷á¬øàܨì¶×âÖå)
  • spontaneous mutation
    "ÀÚ¿¬º¯ÀÌ(í»æÔܨì¶), ÀúÀý·Îº¯ÀÌ(ܨì¶)"
  • subvital mutation
    ¾ÆÄ¡¸í º¯ÀÌ(ä¬öÈ٤ܨì¶)
  • suppressor mutation
    ¾ï¾Ð(ÀÚ)º¯ÀÌ(åääâ(í­)ܨì¶)
  • transverse mutation
    ¿°±âº¯È¯º¯ÀÌ(ç¤ÐñܨüµÜ¨ì¶)
  • umber mutation
    ¾Ï¹ö º¯ÀÌ
  • unstable mutation
    ºÒ¾ÈÁ¤(ÝÕäÌïÒ) º¯ÀÌ(ܨì¶)
  • up promoter mutation
    ÇÁ·Î¸ðÅÍ Ç×Áø(ùñòä) º¯ÀÌ (ܨì¶)
  • visible mutation
    °¡½Ã º¯ÀÌ(ʦãÊܨì¶)
  • zero-point mutation
    ¿µÁ¡(ÖÃïÇ) º¯ÀÌ(ܨì¶)
  • A chain
    A »ç½½
  • amino acid side chain
    ¾Æ¹Ì³ë»ê(ß«) °ç»ç½½
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
BCAA Branched Chain Amino Acid
MCT Medium Chain Triglyceride
PCR Polymerase Chain Reaction
SCC   1) Sude Chain-Cleavage Complex
  2) Squamous Cell Carcinoma
VLCFA Very Long Chain Fatty Acids
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
BCAA Branched Chain Amino Acid
BCKA Branched chain alpha-ketoacid
BCKAD Branched chain alpha-ketoacid dehydrogenase
BCKDH Branched chain alpha-ketoacid dehydrogenase
BCKA Branched-chain keto acid
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
temperature sensitive mutation <genetics, molecular biology> A type of conditional mutation in organism, somatic cell or virus that makes it possible to study genes whose total inactivation would be lethal. Such ts mutations can also make possible studies of the effect of reversible switching by temperature changes) in expression of the mutated gene. The usual mechanism of temperature sensitivity is that the mutated gene codes for a protein with a temperature dependent conformational instability, so that it possesses normal activity at one temperature (the permissive temperature), but is inactive at a second (nonpermissive) temperature.
(18 Nov 1997)
transition mutation A point mutation involving substitution of one base-pair for another, i.e., replacement of one purine for another and of one pyrimidine for another pyrimidine without change in the purine-pyrimidine orientation.
(05 Mar 2000)
transversion mutation A point mutation involving base substitution in which the orientation of purine and pyrimidine is reversed, in contradistinction to transition mutation.
(05 Mar 2000)
umber mutation A mutation yielding the termination codon UGA, resulting in premature termination of a polypeptide chain.
Compare: suppressor mutation.
Synonym: opal mutation.
(05 Mar 2000)
unstable mutation <molecular biology> A mutation that has a high likelihood of reverting to its original form.
(13 Nov 1997)
up mutation <molecular biology> Refers to any mutation in the promoter region of a gene which can trigger transcription initiation.
(09 Oct 1997)
up promoter mutation A mutation that increases the frequency of initiation of transcription.
(05 Mar 2000)
forward mutation Any mutation which renders a formerly functional gene nonfunctional.
Compare: back mutation.
(09 Oct 1997)
frameshift mutation <molecular biology> A type of mutation that results from insertion or deletion of a single nucleotide into, or from, an open reading frame in the normal DNA sequence.
Normally, the genetic code is read in the wrong frame, three nucleotides at a time, and the entire sequence downstream of the mutation, is translated into a polypeptide with a garbled amino acid sequence from the mutated codon onwards. These mutations may be induced by certain types of mutagens or may occur spontaneously and usually result in the generation, downstream, of nonsense, chain termination codons.
Synonym: addition mutation, addition-deletion mutation, deletion mutation, reading-frameshift mutation.
(21 Jun 2000)
lethal mutation <genetics, molecular biology> Mutation that eventually results in the death of an organism carrying the mutation.
(18 Nov 1997)
A chain A polypeptide component of insulin containing 21 amino acyl residues, beginning with a glycyl residue (NH2-terminus); insulin is formed by the linkage of an A chain to a B chain by two disulfide bonds; the amino-acid composition of the A chain is a function of species.
Synonym: glycyl chain.
In general, one of the polypeptides in a multiprotein complex.
(05 Mar 2000)
alpha chain disease A vague or indefinite term; could be used for alpha-heavy-chain disease (a lymphoplasma cell proliferative disease usually seen in Mediterranean men, characterised by intestinal involvement with steatorrhoea, often progressive with fatal outcome) or a thalassaemia (a genetic abnormality in the alpha globin chain of haemoglobin).
(05 Mar 2000)
amino acids, branched-chain Amino acids which have a branched carbon chain.
(12 Dec 1998)
B chain A polypeptide component of insulin containing 30 amino acyl residues, beginning with a phenylalanyl residue (NH2-terminus); insulin is formed by the linkage of a B chain to an A chain by two disulfide bonds; the amino-acid composition of the B chain is a function of species.
Synonym: phenylalanyl chain.
(05 Mar 2000)
behaviour chain Related behaviours in a series in which each response serves as a stimulus for the next response.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • door chain
    µµ¾ð üÀÎ(¹æ¹ü¿ë ¹®ÀÇ ¼è»ç½½)
  • drag chain
    (±â)¹ÙÄû ¸ØÃß´Â ¼è»ç½½;(Â÷·®ÀÇ)¿¬°á »ç½½;(ºñÀ¯)Àå¾Ö¹°;¹æÇع°
  • fission chain reaction
    Çٺп­ ¿¬¼â ¹ÝÀÀ
  • fob chain
    ½Ã°èÁÙ(²ö,¸®º»)
  • food chain 1
    ¸ÔÀÌ¿¬¼â;½Ä·áǰ ¿¬¼âÁ¡
  • guard chain
    (½Ã°è µûÀ§ÀÇ)»ç½½ÁÙ
  • heavy chain
    (¸é¿ª ±Û·ÎºÒ¸°ÀÇ)Áß¿¬¼â
  • light chain
    Àü±â ½ºÅĵåÀÇ ²ö
  • mountain chain
    »ê¸Æ
  • watch chain
    ȸÁß ½Ã°èÀÇ ¼èÁÙ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á